相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
Isabelle Ollivier-Hourmand et al.
JOURNAL OF HEPATOLOGY (2022)
Baveno VII - Renewing consensus in portal hypertension
Roberto de Franchis et al.
JOURNAL OF HEPATOLOGY (2022)
Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
Isabelle Ollivier-Hourmand et al.
JOURNAL OF HEPATOLOGY (2022)
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial
Candid Villanueva et al.
LANCET (2019)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Rebleeding Prophylaxis Improves Outcomes in Patients With Hepatocellular Carcinoma: A Multicenter Case-Control Study
Cristina Ripoll et al.
HEPATOLOGY (2013)
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
M. Pinter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats
Marc Mejias et al.
HEPATOLOGY (2009)
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2009)
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats
M Fernandez et al.
JOURNAL OF HEPATOLOGY (2005)
分享论文
